Trulicity dulaglutide

The single highest-value commercial intervention is a structured peer-to-peer "survive the first 8 weeks" program: the GI tolerance window is the primary abandonment gate, and patients who cross it become vocal brand champions.

• GI side effects (nausea 40%, diarrhea 24%, vomiting 18% by patient self-report) are the dominant abandonment driver in weeks 1-8, but patients who persist past dose-titration frequently flip to strong advocates citing dramatic A1C and weight wins.
• Cost and access anxiety runs parallel to tolerability fear: retail prices near $1,300/month without insurance drive pre-fill abandonment and mid-therapy discontinuation, especially among Medicare patients excluded from the Lilly Savings Card.
• Switching pressure toward semaglutide (Ozempic) and tirzepatide (Mounjaro/Zepbound) is real and accelerating, driven by physician-cited superiority data in head-to-head trials and patient perception of greater weight-loss potential with newer agents.
• An emerging muscle-loss narrative across the GLP-1 class is landing in Trulicity patient forums, creating new hesitancy about long-term body composition outcomes that the brand has not yet meaningfully addressed in patient-facing messaging.